SOUTH SAN FRANCISCO, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the sale of 9,090,909 shares of its common stock for aggregate gross proceeds of approximately $30.0 million before commissions and offering expenses under its previously announced “at-the-market” equity offering program. The sales were completed pursuant to the Sales Agreement between the company and Cowen and Company, LLC, which the company filed as an exhibit to a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on August 3, 2017. The sales exhausted the shares that were available for sale under the Sales Agreement.
A shelf registration statement on Form S-3 relating to the common stock offered in the public offering described above was filed with the SEC on April 28, 2017 and declared effective by the SEC on May 2, 2017. The offering was made only by means of a written prospectus and prospectus supplements that form a part of the registration statement. Prospectus supplements and an accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website at www.sec.gov. Copies of the prospectus supplements and accompanying prospectus may also be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806.
This press release does not constitute an offer to sell or the solicitation of an offer to buy shares of common stock, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Fluidigm and the Fluidigm logo are trademarks or registered trademarks of Fluidigm Corporation.
Contact: Fluidigm Corporation Ana Petrovic Director, Corporate Development and Investor Relations 650.243.6628 (Office) firstname.lastname@example.org